More on Edwards Life Sciences (EW): Q4 beats on EPS but misses on revenue, due in large part to...

|About: Edwards Lifesciences Corp (EW)|By:, SA News Editor

More on Edwards Life Sciences (EW): Q4 beats on EPS but misses on revenue, due in large part to the late approval of Sapien, its catheter-delivered heart valve. The device gained FDA approval in late November and saw only marginal sales impact during the quarter. Shares -4.3% AH.